Singapore markets closed
  • Straits Times Index

    3,153.14
    -4.83 (-0.15%)
     
  • S&P 500

    4,240.76
    -6.68 (-0.16%)
     
  • Dow

    34,319.69
    -159.91 (-0.46%)
     
  • Nasdaq

    14,102.00
    +32.58 (+0.23%)
     
  • BTC-USD

    40,579.01
    +4,664.63 (+12.99%)
     
  • CMC Crypto 200

    1,006.90
    +38.05 (+3.93%)
     
  • FTSE 100

    7,166.95
    +32.89 (+0.46%)
     
  • Gold

    1,869.10
    -10.50 (-0.56%)
     
  • Crude Oil

    71.54
    +0.63 (+0.89%)
     
  • 10-Yr Bond

    1.4820
    +0.0200 (+1.37%)
     
  • Nikkei

    29,161.80
    +213.07 (+0.74%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • FTSE Bursa Malaysia

    1,582.46
    +7.30 (+0.46%)
     
  • Jakarta Composite Index

    6,080.38
    -15.11 (-0.25%)
     
  • PSE Index

    6,917.49
    +9.70 (+0.14%)
     

Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May:

  • Bank of America 2021 Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. E.T.

  • UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 10:00 a.m. E.T.

A live audio webcast of each presentation can be accessed via the Investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Andrew Faughnan
Sr. Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G